Cure My Disease

Don't miss your cure!

 Log in / Sign up

New growth hormone drug ngenla tracked for Long-Term safety in kids

NCT ID NCT05602766

Disease control Sponsor: Pfizer Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study follows children with growth hormone deficiency who are starting Ngenla for the first time. Researchers will monitor their growth and any side effects over several years, until November 2027. The goal is to understand the long-term safety and effectiveness of this daily injection in real-world use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Ngenla (somatrogon), a growth hormone injection
What this could lead to
If successful, this study could confirm that Ngenla is safe and effective for long-term use in children with growth hormone deficiency, supporting its continued use in daily practice.
What could go wrong
This is a small, single-patient observational study, not a large controlled trial. Results may not apply to all patients, and long-term risks like glucose disorders or tumors need monitoring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1 person

The number who actually took part.

Started

Feb 2023

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with GHD without epiphyseal closure who received NGENLA

Ages

Up to 15 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Patients who satisfy all of the registration criteria are subject to this study. Registration criteria 1. Patients with GHD without epiphyseal closure who receive this drug for the first time after the date of contract for this study. 2. Boys who are less than 15 years and girls who are less than 13 years of chronological age at the start of treatment with this drug.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Growth hormone deficiency without epiphyseal closure are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pituitary dwarfism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Growth hormone deficiency without epiphyseal closure

Contacts and locations

Locations

  • Pfizer

    Tokyo, Japan